2021
DOI: 10.1136/ejhpharm-2021-002955
|View full text |Cite
|
Sign up to set email alerts
|

Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain

Abstract: Objective To assess the economic impact of introducing biosimilars of bevacizumab for the management of cancer patients receiving systemic bevacizumab in the National Health System (SNHS) of Spain. Methods A 3-year budget impact analysis model was adapted to estimate the cost of introducing biosimilars of bevacizumab in the SNHS for the adult population who were candidates to receive treatment with bevacizumab. Values for the estimation of the population were obtained f… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3
2

Relationship

0
5

Authors

Journals

citations
Cited by 11 publications
references
References 19 publications
0
0
0
Order By: Relevance